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JoBackground: Combined congenic breeding and
microarray gene expression profiling previously identified
glutathione S-transferase m-type 1 (Gstm1) as a positional
and functional candidate gene for blood pressure (BP)
regulation in the stroke-prone spontaneously hypertensive
(SHRSP) rat. Renal Gstm1 expression in SHRSP rats is
significantly reduced when compared with normotensive
Wistar Kyoto (WKY) rats. As Gstm1 plays an important
role in the secondary defence against oxidative stress,
significantly lower expression levels may be functionally
relevant in the development of hypertension. The aim of
this study was to investigate the role of Gstm1 in BP
regulation and oxidative stress by transgenic
overexpression of the Gstm1 gene.
Method: Two independent Gstm1 transgenic SHRSP lines
were generated by microinjecting SHRSP embryos with a
linear construct controlled by the EF-1a promoter encoding
WKY Gstm1 cDNA [SHRSP-Tg(Gstm1)1WKY and SHRSP-
Tg(Gstm1)2WKY].
Results: Transgenic rats exhibit significantly reduced BP and
pulse pressure when compared with SHRSP [systolic: SHRSP
205.23.7mmHg vs. SHRSP-Tg(Gstm1)1WKY
175.51.6mmHg and SHRSP-Tg(Gstm1)2WKY
1723.2mmHg, P<0.001; pulse pressure: SHRSP
58.40.73mmHg vs. SHRSP-Tg(Gstm1)1WKY
52.70.19mmHg and SHRSP-Tg(Gstm1)2WKY
40.750.53mmHg, P<0.001]. Total renal and aortic
Gstm1 expression in transgenic animals was significantly
increased compared with SHRSP [renal relative quantification
(RQ): SHRSP-Tg(Gstm1)1WKY 1.95 vs. SHRSP 1.0, P<0.01;
aorta RQ: SHRSP-Tg(Gstm1)1WKY 2.8 vs. SHRSP 1.0,
P<0.05]. Renal lipid peroxidation (malondialdehyde: protein)
and oxidized : reduced glutathione ratio levels were
significantly reduced in both transgenic lines when compared
with SHRSP [malondialdehyde: SHRSP 0.040.009mmol/l
vs. SHRSP-Tg(Gstm1)1WKY 0.0240.002mmol/l and SHRSP-
Tg(Gstm1)2WKY 0.0210.002mmol/l; (oxidized : reduced
glutathione ratio): SHRSP 5.192.26mmol/l vs. SHRSP-
Tg(Gstm1)1WKY 0.170.111mmol/l and SHRSP-
Tg(Gstm1)2WKY 0.4710.223mmol/l]. Transgenic SHRSP
rats containing the WKY Gstm1 gene demonstrate
significantly lower BP, reduced oxidative stress and improved
levels of renal Gstm1 expression.urnal of HypertensionConclusion: These data support the hypothesis that
reduced renal Gstm1 plays a role in the development of
hypertension.
Keywords: glutathione S-transferase m-type 1,
hypertension, oxidative stress, stroke-prone spontaneously
hypertensive rat, transgenic
Abbreviations: BP, blood pressure; GSSG : GSH,
oxidizedreduced glutathione ratio; GSTM1, glutathione
S-transferase m-type 1; LVMI, left ventricular mass index/
indices; PP, pulse pressure; QTL, quantitative trait locus/
loci; RMI, renal mass index/indices; ROS, reactive oxygen
species; SHRSP, stroke-prone spontaneously hypertensive
rat; WKY, Wistar KyotoINTRODUCTIONH
uman essential hypertension is a complex poly-
genic disease with genetic heritability averaging
approximately 40% and with strong influence of
environmental factors and gene–environment interaction
[1,2]. Heterogeneity in the general population and the
polygenic complexities of the disease has meant that iden-
tification and functional validation of candidate genes has
proved difficult in humans. A range of studies including
genome wide association studies, meta-analysis and admix-
ture mapping studies have successfully identified numer-
ous loci associated with phenotypic variance for SBP andDOI:10.1097/HJH.0000000000001960
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ance of blood pressure (BP) (i.e. 5%) is explained by
the loci discovered so far. To fully understand the func-
tional roles of genetic loci on BP regulation it is essential
to interrogate their impact in suitable rodent models.
Rodent models are commonly used to discern and dissect
genetic determinants of hypertension as they offer more
favourable investigative opportunities because of
reduced genetic heterogeneity, the capacity for con-
trolled breeding and environmental conditions, and the
ability to produce genetic crosses and analyse large
numbers of progeny [16,17]. This translational approach
will improve our knowledge and understanding of path-
ways, networks and gene environment interaction under-
lying essential hypertension.
The stroke-prone spontaneously hypertensive rat
(SHRSP) is a well characterized experimental model for
human essential hypertension, which develops a number
of cardiovascular complications, including cardiac hyper-
trophy and stroke [18–20]. Similar to human disease, the
genetic determination of BP variation in this model is
complex and the result of multiple gene–gene and
gene–environment interactions [21,22]. Genome-wide
linkage studies have proved successful in the localization
of large chromosomal regions containing quantitative trait
loci (QTLs) for blood regulation in the SHRSP. In particu-
lar, previous work in our laboratory has identified at least
two BP QTLs mapping to rat chromosome 2 [20]. These
QTL were subsequently confirmed with the production
and phenotypic analysis of chromosome 2 congenic
strains, generated by introgressing regions of rat chromo-
some 2 from the normotensive Wistar Kyoto (WKY) strain
into the SHRSP genetic background. This resulted in
significant reduction of SBP and DBP when the congenic
strains were compared with the SHRSP parental strain
[23,24].
Combining this congenic strategy with genome-wide
microarray expression profiling allowed the identification
of the positional candidate gene, glutathione S-transferase
m-type 1 (Gstm1) [24,25]. This gene encodes a cytoplasmic
glutathione S-transferase (GST) that belongs to the mu class
of GST enzymes, which function in the detoxification of
electrophilic compounds, including carcinogens, therapeu-
tic drugs, environmental toxins and products of oxidative
stress, by conjugation with glutathione [26]. GSTM1 protein
is expressed in a wide range of tissues including the liver,
endocrine tissues, brain, muscle tissues and kidney [27].
Our previous studies in the SHRSP rat demonstrate signifi-
cantly downregulated expression of Gstm1 in the kidney
when compared with the WKY. As a result of this reduced
Gstm1 expression we hypothesise that the secondary
defence against oxidative stress is compromised in SHRSP
rats leading to oxidative stress-induced hypertension and
end organ damage.
The aim of this study was to establish conclusive
evidence that reduced Gstm1 expression affects BP
regulation and oxidative stress. Two independent
SHRSP transgenic lines were created with the aim of
reversing Gstm1 deficiency by incorporation of the
Gstm1 gene from the normotensive WKY strain into
the SHRSP genome.2 www.jhypertension.comMATERIAL ANDMETHODS
Animal strains
Inbred colonies of SHRSP and WKY have been maintained
at the University of Glasgow since 1991, as described
previously [20]. All animals were housed under controlled
environmental conditions, fed standard rat chow (rat and
mouse no. 1 maintenance diet, Special Diet Services) and
water provided ad libitum. All animal procedures per-
formed were approved by the Home Office according to
regulations regarding experiments with animals in the
United Kingdom.
Transgenic rat generation
Two independent transgenic lines of Gstm1 SHRSP rats
were created through incorporation of theGstm1 gene from
the normotensive WKY strain into the SHRSP genome,
which are designated SHRSP-Tg(Gstm1)1WKY and SHRSP-
Tg(Gstm1)2WKY. Generation of these transgenic SHRSP rats
involved microinjection of a 2.7-kb linear construct encod-
ing wild-type (WKY) Gstm1 under the control of the uni-
versal EF-1a promoter (Supplementary Fig. 1, http://
links.lww.com/HJH/B27). They were generated using the
same expression platform and microinjection fragment
purification protocol employed as previously described
[28]. See Supplementary file for extended methods.
Phenotypic measurements
The Dataquest IV telemetry system (Data Sciences Interna-
tional) was used for the direct measurement of SBP, DBP,
pulse pressure (PP), activity and heart rate (HR) [23,29].
Male rats were implanted at 12 weeks of age with 1-week
recovery, and haemodynamic parameters recorded until
rats were 21 weeks of age. BP prior to 12 weeks of age was
measured by tail cuff plethysmography [30]. Metabolic
cages were used to collect 24-h urine samples from all
animals before sacrifice. At sacrifice, weights for cardiac
mass index, left ventricular (LV) mass index (LVMI) and
renal mass index (RMI) were measured and corrected to
tibia length. At sacrifice a range of tissues were harvested
and either snap frozen in liquid nitrogen and stored at
80 8C or fixed in 4% buffered formaldehyde and paraffin
embedded for histology or immunohistochemistry (IHC).
Urinary protein was measured using Thermo Pierce
Protein Assay 660 (no. 22662; Thermo Fisher Scientific
Inc, Waltham, Massachusetts, USA) with samples diluted
one in five for assay. Urinary biochemistry analysis was
carried out using a Beckman Coulter AU640 clinical chem-
istry analyser utilizing ion selective electrodes. Indirect
glomerular filtration rates (GFR) were determined by a
clinically validated automated analyser (c311, Roche Diag-
nostics, Burgess Hill, UK), using the manufacturer’s cali-
brators and quality control material for isotope dilution-
mass spectrometry. All measurements were normalized to
kidney weight.
Echocardiography
Transthoracic echocardiography was used to assess cardiac
geometry and contractility, as previously described [30,31].
Echocardiography was performed prior to sacrifice at
21 weeks of age. Animals were sedated and short axisVolume 36  Number 1  Month 2018
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Rat model of glutathione S-transferase m-type overexpression2-dimensional B-mode and M-mode images were taken
through the left parasternal window at the papillary muscle
levels using an ACUSON Sequoia C512 Echocardiograph
(Siemens, Erlangen, Germany). Averaged data from six
consecutive cardiac cycles from each M-mode tracing were
used in the following equation for the calculation of LV
mass [American society of echocardiography (ASE)-cube
formula with Devereux correction factor] [LV mass¼ 0.8
(1.04 ((EDDþPWTþAWT) 3EDD3))þ 0.6], where PWT
is the posterior wall thickness (mm), AWT is the anterior
wall thickness (mm), EDD is the end diastolic dimension
(mm). LV end-systolic volume (ESV) and LV end-diastolic
volume (EDV) can be calculated from two-dimensional
images according to a modified Simpson’s rule. LV ejection
fraction (LVEF) is then determined from EDV and ESV.
Cardiac index is estimated as cardiac output (CO) adjusted
for tibia length.
Renal histology
To assess evidence of renal disease, 3mm sections from
WKY, SHRSP and transgenic rat kidneys were stained with
Harris haematoxylin and eosin and examined using an
Olympus DP72 camera attached to Olympus BX51 micro-
scope, and analysed using DP2-BSW software (Olympus,
Hamburg, Germany).
Quantitative real-time PCR
Total RNA was extracted from kidney, aorta, heart and brain
tissues from 5-week-old and 21-week-old rats using RNeasy
kits (Thermo Fisher Scientific Inc.), treated with DNase Free
(Thermo Fisher Scientific Inc.) and quantified using Ribo-
green (Thermo Fisher Scientific Inc.). Normalization was
confirmed by performing real-time PCR on TaqMan
(Thermo Fisher Scientific Inc.) of b-actin with comparable
threshold cycles. TaqMan probes for Gstm1
(Rn00755117m1-labeled FAM) and b-actin (4352340E-
labeled VIC) were multiplexed. Expression of Gstm1 rela-
tive to b-actin in each sample was derived using the
comparative (DDCT) method [25].
For transgene or WKY (wild-type) gene expression,
Exiqon custom locked-nucleic acid SYBR Green probes
were designed to single nucleotide polymorphism (SNP)
differences between WKY and SHRSP in exon 8 as previ-
ously described [25].
Western analysis of glutathione S-transferase
m-type 1 in rat kidney
Kidneys from 5-week-old and 21-week-old SHRSP, WKY
and SHRSP-Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY
rats were homogenized in protease inhibitor-containing
buffer. Protein concentration was determined using a
Bio-Rad BCA kit. Proteins were separated by PAGE and
electroblotted onto a Hybond-P membrane (Thermo Fisher
Scientific Inc,). Membranes were incubated with the appro-
priate primary antibody (anti-GSTM1 [25] 1 : 5000, antib-
actin 1 : 1000) before repeated washing and application of a
horseradish peroxidase-conjugated secondary antibody.
Protein bands were detected by chemiluminescence (ECL
kit; Thermo Fisher Scientific Inc), and visualized and quan-
tified using a Bio-Rad Image Analyzer densitometry system.Journal of HypertensionImmunohistochemistry
Sections (6mm) were obtained from kidneys and aorta of
SHRSP, WKY, SHRSP-Tg(Gstm1)1WKY and SHRSP-
Tg(Gstm1)2WKY male rats. Sections were blocked for
60min with 2% serum in PBS, followed by overnight
incubation at 26 8C with an antibody against GSTM1 [25].
A biotinylated secondary antibody, diluted in blocking
reagent (ABC universal kit, two drops blocking ser-
umþ two drops supplied vectastain biotinylated antibo-
dyþ 5ml PBS) was added for 30 min at room
temperature (RT). 3,3’-Diaminobenzidine (DAB) chromo-
gen (DAB substrate kit) for universal and peroxidase sec-
ondary antibody was prepared following manufacturer’s
instructions. After treatment with antigen retrieval solution
(Agilent, Stockport, Cheshire, UK), sections were blocked
with 20% serum in PBS for 1 h. Washing with PBS was
followed by incubation with a secondary antibody, at RT for
1 h. Sections were counterstained with Haematoxylin.
Images shown were taken with Olympus DP72 attached
to Olympus BX51 microscope, using DP2-BSW software
(Olympus, Hamburg, Germany).
Oxidative stress measurements
Superoxide, hydrogen peroxide, nitric oxide, glutathione
and lipid peroxidation measurements were performed in
homogenized snap-frozen tissues from 5-week-old and 21-
week-old animals. Superoxide was measured using lucige-
nin chemiluminescence in kidney tissue homogenized in
lysis buffer [20mmol/l of KH2PO4, 1mmol/l of ethylene
glycol-bis(B-aminoethyl ether)-N,N,N’,N’-tetraacetic acid
(EGTA), 1mg/ml of aprotinin, 1mg/ml of leupeptin, 1mg/
ml of pepstatin and 1mmol/l of phenylmethylsulfonyl fluo-
ride (PMSF)]. Fifty microliters of the sample were added to a
suspension containing 175ml of assay buffer (50mmol/l of
KH2PO4, 1mmol/l of EGTA, and 150mmol/l of sucrose) and
lucigenin (5mmol/l). NADPH (104 mol/l) was added to the
suspension (300ml) containing lucigenin. Luminescencewas
measured every 18 s for 3min by a luminometer (AutoLumat
LB 953; Berthold Technologies, Wildbad, Germany) before
and after stimulation with NADPH. A buffer blank was
subtracted from each reading. The results are expressed as
counts per milligram of protein (percentage of control).
Glutathione levels were measured according to Cayman
Glutathione Assay Kit (#703002) manufacturer’s instructions.
Hydrogen peroxide levels were measured using Invitrogen’s
AmplexR Red Hydrogen Peroxide/Peroxidase Assay Kit
Amplex Red (Thermo Fisher Scientific Inc.) for tissues. Total
nitrate and nitrite concentrations were measured using the
Cayman Biochemical Nitrate/Nitrite Colorimetric Assay Kit.
Statistical analysis
Results are expressed as mean SEM. Haemodynamic
parameters for WKY or transgenic strains were compared
with SHRSP, using repeated measures analysis of variance
(ANOVA) (general linear model). The night–day PP differ-
ence was calculated as night PP (mmHg)-day PP (mmHg).
Other phenotypic comparisons between groups were per-
formed by one way ANOVA with Tukey’s multiple compari-
son test, unless stated otherwise. For cardiac parameter
analysis statistical analysiswas performedbya Student’s t test.www.jhypertension.com 3
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Haemodynamic parameters
When measured by radiotelemetry, SHRSP-Tg(Gstm1)1WKY
and SHRSP-Tg(Gstm1)2WKY rats demonstrated significantly
reduced SBP (Fig. 1a), and PP (Fig. 1c) when compared
with SHRSP (P< 0.001). DBP (Fig. 1b) and mean arterial
pressure (Fig. 1d) were significantly reduced across the
entire analysis period in SHRSP-Tg(Gstm1)1WKY rats,
whereas SHRSP-Tg(Gstm1)2WKY rats demonstrated a signif-
icant reduction in diastolic and mean arterial pressure from
approximately 18 weeks of age onwards (P< 0.001). There
were no significant differences in HR or activity level across
the measurement period between the four strains (Supple-
mentary Fig. 2, http://links.lww.com/HJH/B27). Before 12
weeks of age, SBP measured by tail cuff plethysmography
was significantly lower in WKY and the transgenic lines
when compared with SHRSP (P< 0.001) (Supplementary
Table 1, http://links.lww.com/HJH/B27).
Cardiac parameters
Cardiac parameters were assessed in rats at 21 weeks of age
by transthoracic echocardiography immediately prior to
sacrifice. LVMI was significantly reduced in WKY and120
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FIGURE 1 Haemodynamic parameters in SHRSP-Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY
and (d) mean arterial pressure was observed in SHRSP-Gstm1)1WKY (n¼12), SHRSP-Tg(G
(n¼12). Blood pressure was measured by radiotelemetry, and data illustrate weekly aver
transferase-m-type-1; SHRSP, stroke-prone spontaneously hypertensive.
4 www.jhypertension.comSHRSP-Tg(Gstm1)2WKY hearts compared with that of the
SHRSP (P< 0.05). SHRSP-Tg(Gstm1)1WKY rats displayed a
trend towards a reduction in LVMI but didnot reach statistical
significance (Fig. 2a). Relative wall thickness in SHRSP-
Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY and WKY rats
was significantly lower compared with that of the SHRSP
(F¼ 7.9, P< 0.05) (Fig. 2b). Stroke volume (SV) for SHRSP
rats was significantly decreased when compared with WKY,
SHRSP-Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY rats
(Fig. 2c). CO in SHRSP rats was significantly decreased when
compared with WKY, SHRSP-Tg(Gstm1)1WKY and SHRSP-
Tg(Gstm1)2WKY rats (Fig. 2d). There were no significant
differences in LV fractional shortening or ejection fraction
between WKY, SHRSP, SHRSP-Tg(Gstm1)1WKY and SHRSP-
Tg(Gstm1)2WKY (data not shown).
Renal parameters
Renal function data at 21 weeks of age are given in Table 1.
Although there was a trend towards increased estimated
GFR in SHRSP-Tg(Gstm1)1WKY rats, there was no signifi-
cance difference between all four strains (P> 0.05). There
was also no significant difference between all four strains
for urine sodium, potassium and chloride levels (P> 0.05).
Levels of proteinuria in WKY, SHRSP-Tg(Gstm1)1WKY and80
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FIGURE 2 Cardiac parameters in SHRSP-Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY and parental strains. Significantly reduced (a) left ventricular mass index and (b) relative
wall thickness, and significantly elevated (c) stroke volume, and (d) cardiac output were observed in SHRSP-Tg(Gstm1)1WKY (n¼8), SHRSP-Tg(Gstm1)2WKY (n¼6) and
Wistar Kyoto rats (n¼8) when compared with SHRSP (n¼8). Cardiac parameters were measured by echocardiography at 21 weeks (P<0.05, P<0.01, P<0.001).
TL, tibia length, Trans 1, SHRSP-Tg(Gstm1)1WKY, Trans 2, SHRSP-Tg(Gstm1)2WKY. Gstm1, glutathione-S-transferase-m-type-1; SHRSP, stroke-prone spontaneously hyperten-
sive.
Rat model of glutathione S-transferase m-type overexpressionSHRSP-Tg(Gstm1)2WKY rats were significantly lower than
that of the SHRSP (P< 0.05). At 21 weeks of age, kidney
mass, normalized to body weight, was significantly lower in
WKY when compared with SHRSP (P< 0.0001). RMI for
SHRSP-Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY rats
was not significantly different when compared with
SHRSP.
Renal morphology, assessed by haemotoxylin and eosin
staining at 21 weeks of age, showed normal arterioles in the
WKY and transgenic animals, however renal arterioles in
the SHRSP showed evidence of hyperplasia, a sign of
accelerated hypertension (Fig. 3).TABLE 1. Renal parameters in SHRSP, Wistar Kyoto, SHRSP-Tg(Gstm1
SHRSP WK
GFR (ml/min) 1.5650.206 1.642
Na2þ (mg/ml) 83.9811.13 78.24
Kþ (mg/ml) 116.214.02 149.1
Cl (mg/ml) 100.110.84 148.7
RMI 4.2420.044 3.389
Proteinuria (mg/g) 29.985.32 9.765
GFR, glomerular filtration rate; n¼ 6–8 per group; Gstm1, glutathione-S-transferase-m-type-1; R
(Gstm1)1WKY; Trans 2, SHRSP-Tg (Gstm1)2WKY; WKY, Wistar Kyoto.
P<0.05 vs. SHRSP.
Journal of HypertensionRenal glutathione S-transferase m-type 1 mRNA
and protein expression
Total Gstm1 mRNA expression (Fig. 4a) and transgene
specific (WKY variant of Gstm1) mRNA expression
(Fig. 4b) in kidneys from rats at 5 weeks of age was
significantly higher in SHRSP-Tg(Gstm1)1WKY, SHRSP-
Tg(Gstm1)2WKY and WKY rats compared with SHRSP
(P< 0.05). This increase in renal Gstm1 mRNA expression
was paralleled by GSTM1 protein levels in SHRSP-
Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY rats. Western
blot analysis indicated significantly increased GSTM1 pro-
tein expression in SHRSP-Tg(Gstm1)2WKY and WKY when)1WKY and SHRSP-Tg(Gstm1)2WKY rats at 21 weeks of age
Y Trans 1 Trans 2
0.137 2.3690.309 1.6050.265
8.433 59.297.533 76.2720.70
14.09 153.023.60 115.130.08
30.58 99.9315.76 110.630.99
0.049 4.3550.366 4.1150.142
4.776 8.4645.771 6.9422.810
MI, renal mass index (kidney/body weight ratio); SHRSP, SHRSP; Trans 1, SHRSP-Tg
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FIGURE 3 Representative renal histology. Kidney sections from rats at 21 weeks of age were stained with haematoxylin and eosin staining and showed no evidence of
vascular pathology in Wistar Kyoto, SHRSP-Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY rats, but evidence of vascular hyperplasia was observed in SHRSP. Arrows indicate
arcuate arteries. Bar¼100mmol/l. Trans 1, SHRSP-Tg(Gstm1)1WKY, Trans 2, SHRSP-Tg(Gstm1)2WKY. Gstm1, glutathione-S-transferase-m-type-1; SHRSP, stroke-prone sponta-
neously hypertensive.
Olson et al.compared with SHRSP, with a trend towards an increase in
kidneys from SHRSP-Tg(Gstm1)1WKY rats (Fig. 4c and d).
IHC in kidneys from 5-week-old rats confirmed increased
protein expression within the distal tubules of WKY and
SHRSP-Tg(Gstm1)1WKY rats when compared with SHRSP
(Fig. 4e).
At 21 weeks of age, total renal Gstm1 mRNA expression
(Fig. 5a) and transgene specific mRNA expression (Fig. 5b)
were significantly higher in WKY rats when compared with
with SHRSP (P< 0.05). Transgene specific mRNA expres-
sion was also significantly increased in SHRSP-
Tg(Gstm1)1WKY rats, however SHRSP-Tg(Gstm1)2WKY rats
showed low transgene expression, which was not different
from SHRSP (Fig. 5b). GSTM1 protein levels were signifi-
cantly higher in WKY rats compared with that of the SHRSP
(P< 0.01) but were not significantly different in SHRSP-
Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY rats com-
pared with SHRSP (P> 0.05) (Fig. 5c and d). IHC confirmed
an increase in GSTM1 protein expression in distal
tubules of WKY rats compared with SHRSP, with no
increase in GSTM1 protein expression in the transgenic
rats (Fig. 5e).6 www.jhypertension.comVascular glutathione S-transferase m-type 1
mRNA expression and immunohistochemistry
At 5 weeks of age vascular (aortic) total Gstm1 expression
showed a trend towards an increase in SHRSP-
Tg(Gstm1)1WKY and WKY rats, and was significantly
increased in SHRSP-Tg(Gstm1)2WKY rats when compared
with the SHRSP (P< 0.05) (Supplementary Fig. 3A, http://
links.lww.com/HJH/B27). At 21 weeks of age, Gstm1
mRNA expression in aorta was significantly increased in
SHRSP-Tg(Gstm1)1WKY and WKY rats when compared with
and SHRSP (P< 0.005) (Supplementary Fig. 3B, http://link-
s.lww.com/HJH/B27). However, aortic Gstm1 expression
in SHRSP-Tg(Gstm1)2WKY rats showed an increased trend
but was not significantly different from WKY, SHRSP-
Tg(Gstm1)1WKY or SHRSP rats. IHC was performed on
the aorta at 21 weeks of age to investigate GSTM1 protein
expression. When quantified, percentage staining in the
aorta demonstrated a significant increase in GSTM1 protein
in WKY rats when compared with SHRSP (P< 0.05) (Sup-
plementary Fig. 3C and D, http://links.lww.com/HJH/B27).
There was a trend towards an increase in protein
expression for aortas in SHRSP-Tg(Gstm1)1WKY andVolume 36  Number 1  Month 2018
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FIGURE 4 Renal glutathione S-transferase m-type 1 expression in SHRSP-Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY and parental strains at 5 weeks of age. Glutathione
S-transferase m-type 1 expression in kidney at 5 weeks of age in SHRSP (n¼8), Wistar Kyoto (n¼8), SHRSP-Tg(Gstm1)1WKY (n¼8) and SHRSP-Tg(Gstm1)2WKY (n¼3) rats.
(a) Total Gstm1 mRNA levels were significantly increased in Wistar Kyoto, SHRSP-Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY lines when compared with the SHRSP (P<0.01).
(b) Wistar Kyoto specific glutathione S-transferase m-type 1 mRNA levels were significantly higher in the Wistar Kyoto, SHRSP-Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY
rats when compared with stroke-prone spontaneously hypertensive rats (P<0.05). (c) Representative western blot of whole kidney homogenates from parental and
transgenic rats. (d) Increased glutathione S-transferase m-type 1 protein expression was confirmed by densitometry with each band normalized to b-actin (n¼3 for each
strain) (P<0.05). (e) Immunohistochemistry of glutathione S-transferase m-type 1 protein in whole kidney sections from Wistar Kyoto, SHRSP and SHRSP-Tg(Gstm1)1WKY
rats at 5 weeks of age (magnification¼10). Trans 1, SHRSP-Tg(Gstm1)1WKY, Trans 2, SHRSP-Tg(Gstm1)2WKY. Gstm1, glutathione-S-transferase-m-type-1; SHRSP, stroke-
prone spontaneously hypertensive.
Rat model of glutathione S-transferase m-type overexpression
Journal of Hypertension www.jhypertension.com 7
CE: Swati; JH-D-18-00200; Total nos of Pages: 12;
JH-D-18-00200
FIGURE 5 Renal glutathione S-transferase m-type 1 expression between SHRSP-Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY and parental strains at 21 weeks of age. (a) Total
glutathione S-transferase m-type 1 expression in kidney at 21 weeks of age in SHRSP (n¼8), Wistar Kyoto (n¼8), SHRSP-Tg(Gstm1)1WKY (n¼8) and SHRSP-Tg(Gstm1)2WKY
(n¼6) rats. Total glutathione S-transferase m-type 1 levels were significantly increased in Wistar Kyoto rats when compared with stroke-prone spontaneously hypertensive
rats P<0.01. (b) Wistar Kyoto specific glutathione S-transferase m-type 1 mRNA levels were significantly higher in Wistar Kyoto and SHRSP-Tg(Gstm1)1WKY rats when
compared with SHRSP (P<0.05). Representative western blot (c) illustrates increased glutathione S-transferase m-type 1 expression in Wistar Kyoto when compared with
stroke-prone spontaneously hypertensive rats, which was confirmed by densitometry (d) with each band normalized to b-actin (n¼3 for each strain) (P<0.05). (e)
Immunohistochemistry of glutathione S-transferase m-type 1 protein in whole kidney sections from Wistar Kyoto, SHRSP and SHRSP-Tg(Gstm1)1WKY rats at 21 weeks of
age (magnification¼10). Trans 1, SHRSP-Tg(Gstm1)1WKY, Trans 2, SHRSP-Tg(Gstm1)2WKY. Gstm1, glutathione-S-transferase-m-type-1; SHRSP, stroke-prone spontaneously
hypertensive.
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FIGURE 6 Renal oxidative stress measurements in SHRSP-Tg(Gstm1)1WKY, SHRSP-Tg(Gstm1)2WKY and parental strains at 21 weeks of age. (a) Renal superoxide levels
measured by lucigenin chemiluminescence and (b) hydrogen peroxide levels measured by Amplex Red were not significantly different between stroke-prone spontaneously
hypertensive (n¼8), Wistar Kyoto (n¼8), SHRSP-Tg(Gstm1)1WKY (n¼8) or SHRSP-Tg(Gstm1)2WKY (n¼6) rats. Renal oxidative stress status determined by (c) oxidized : re-
duced glutathione ratio and (d) lipid peroxidation was lower in Wistar Kyoto, SHRSP-Tg(Gstm1)1WKY (n¼8) and SHRSP-Tg(Gstm1)2WKY when compared with stroke-prone
spontaneously hypertensive rats (P<0.05). RLU, relative light unit; Trans 1, SHRSP-Tg(Gstm1)1WKY, Trans 2, SHRSP-Tg(Gstm1)2WKY. Gstm1, glutathione-S-transferase-m-
type-1; SHRSP, stroke-prone spontaneously hypertensive.
Rat model of glutathione S-transferase m-type overexpressionSHRSP-Tg(Gstm1)2WKY rats which was not significantly
different from either parental strain, indicating intermediate
expression (Supplementary Fig. 3D, http://links.lww.com/
HJH/B27).
Cardiac glutathione S-transferase m-type 1
mRNA expression
At 21 weeks of age, cardiac total Gstm1 expression was
significantly increased in the SHRSP-Tg(Gstm1)1WKY line
when compared with WKY and SHRSP (P< 0.05). Cardiac
Gstm1 expression in SHRSP-Tg(Gstm1)2WKY rats showed a
trend towards increase, but was not significantly different
from WKY, SHRSP-Tg(Gstm1)1WKY or SHRSP rats (Supple-
mentary Fig. 4A, http://links.lww.com/HJH/B27).
Effects of glutathione S-transferase m-type 1
expression on renal and cardiac oxidative stress
At 21 weeks of age there was no significant difference
between SHRSP, WKY or the transgenic rat lines for super-
oxide (O2
) levels in whole kidney homogenates (Fig. 6a),
as measured by lucigenin chemiluminesence, or for hydro-
gen peroxide (Fig. 6b), as measured by Amplex Red Assay
(P> 0.05). Oxidized : reduced glutathione (GSSG : GSH)
ratios, showed a trend towards reduced levels in the
WKY and both transgenic lines when compared with theJournal of HypertensionSHRSP at 21 weeks of age (Fig. 6c). Lipid peroxidation
measured using malondialdehyde (MDA) assay showed a
significant reduction in renal MDA production in the WKY,
SHRSP-Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY when
compared with the SHRSP (P< 0.05), Fig. 6d. There were
no significant differences in renal GSSG : GSH ratios
between the four strains at 5 weeks of age (Supplementary
Table 2, http://links.lww.com/HJH/B27), however renal
GSSG : GSH ratios were significantly lower at 5 weeks of
age when compared with 21 weeks of age (Supplementary
Table 2, http://links.lww.com/HJH/B27).
DISCUSSION
In this study, the investigation of two independently gen-
erated transgenic rat lines, SHRSP-Tg(Gstm1)1WKY and
SHRSP-Tg(Gstm1)2WKY, has demonstrated that increased
expression of Gstm1 improves BP regulation and reduces
oxidative stress in the SHRSP rat. Gstm1 deficiency was
reversed by incorporation of the WKY Gstm1 gene into the
SHRSP genome leading to a significant reduction in SBP,
DPB, MAP and PP. These haemodynamic improvements
were paralleled by significant reductions in cardiac hyper-
trophy and improved cardiac function in both transgenic
lines. Furthermore, renal oxidative stress, indicated by lipid
peroxidation and GSSG : GSH ratio, was significantlywww.jhypertension.com 9
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Olson et al.reduced in both transgenic lines when compared with
SHRSP. These findings support the hypothesis that reduced
Gstm1 expression plays a causal role in the development of
oxidative stress and BP elevation in the SHRSP rat.
The method of random transgene integration employed
in this study may be viewed as a limitation when compared
with the locus specific genome editing afforded by clus-
tered regularly interspaced short palindromic repeats
(CRISPR) technology [32]. However, this method for gene
overexpression is still regularly used to generate genetically
engineered rodent models, requires short development
time and importantly is a method that we have previous
success with in rats [33–37]. The generation of more than
one transgenic line, using the same transgene and pro-
moter, is critical to confirm that the phenotypic differences
are the result of the transgene itself and not due to posi-
tional effects caused at the random insertion site. In inde-
pendently generated lines it is highly unlikely that the
transgene will be inserted into the identical genomic posi-
tion. If significant phenotypic changes of similar magnitude
and direction are observed for two independently gener-
ated lines then this provides corroborative evidence that the
phenotype differences are due to a functional effect of
the transgene.
Although both SHRSP-Tg(Gstm1)1WKY and SHRSP-
Tg(Gstm1)2WKY transgenic rats demonstrate improved car-
diovascular profiles, each line showed some unique molec-
ular and phenotypic expression patterns. For example,
while DBP for both SHRSP-Tg(Gstm1)1WKY and SHRSP-
Tg(Gstm1)2WKY lines is significantly lower than that of
SHRSP, the diastolic pressure profiles differ in the rate of
increase over time (Fig. 1b). Similar phenotypic diversity
between two independently generated lines has been
demonstrated in the transgenic rescue of CD36 in the
SHR rat, whereby, unique differences in insulin resistance
and BP regulation were observed between two transgenic
lines despite insertion of the same CD36 transgene and
promoter [28]. It is clear that transgenes often do not behave
as independent units, but are significantly and variably
influenced by a number of factors leading to marked
variations in expression patterns between different trans-
genic lines carrying the same construct [38]. For example,
differences in mRNA and protein expression may occur due
to the impact of enhancers that regulate neighbouring
genes located in close proximity to the inserted transgene
[39]. Although these enhancers normally regulate their
respective associated gene, they can also affect the expres-
sion pattern of a transgene that is inserted near them. In
addition, microinjection has the potential to insert multiple
copies of a transgene into the recipient genome [28,40],
which could lead to distinct copy number profiles within
the two independently generated transgenic lines. Previous
studies in other transgenic models have shown that copy
number influences transgene expression resulting in differ-
ential phenotypic effects [41,42]. Another potential factor
that could impact on the level of transgene expression is
age-related increases in DNA-methylation [43]. For exam-
ple, previous studies in rodent and pig transgenic models
have revealed consistent age-related increases in DNA-
methylation of ribosomal genes that correlated with inhibi-
tion of gene expression [41,44]. Future investigations will be10 www.jhypertension.comnecessary to determine if any of these factors play a role in
the unique expression profiles between SHRSP-
Tg(Gstm1)1WKY and SHRSP-Tg(Gstm1)2WKY rats.
Both transgenic lines demonstrated an increase in total
and transgene specific Gstm1 mRNA expression in kidneys
at 5 weeks of age. However, this increased expression was
not sustained at the later time point investigated (i.e. 21
weeks of age) in the SHRSP-Tg(Gstm1)2WKY line. This
return to SHRSP expression levels at 21 weeks is paralleled
by renal protein expression in both SHRSP-Tg(Gstm1)1WKY
and SHRSP-Tg(Gstm1)2WKY rats. An age-related decline in
transgene expression is not unique to this investigation
since previously published studies have shown that trans-
gene expression levels can decline with time both in vivo
and in vitro [45]. For example, enhanced green fluorescent
protein (EGFP) expression, under the control of the ef1-a
promoter, was found to be progressively limited during the
later stages of development [45], and completely restricted
in adult tissue of Xenopus leavis [46], medaka fish [47] and
zebrafish [43]. Although these studies have reported a
decrease in transgene expression levels during later stages
of life, in line with the present findings, each of these
studies demonstrate significant phenotypic effects as a
result of early transgene expression [43,45–47]. Our data
suggest that enhanced expression of Gstm1 in the kidney
prior to the onset of hypertension prevents the progression
of hypertension in the transgenic SHRSP rat.
The kidney is highly vulnerable to the damage caused by
reactive oxygen species (ROS), which can impact on its
critical role in salt and water homeostasis, leading to altered
renal vascular function and the development of hyperten-
sion [48,49]. In this study, we have demonstrated that the BP
lowering effects of enhanced Gstm1 expression are paral-
leled by reduced oxidative damage in the kidney. Specifi-
cally, Gstm1 transgenic rats show significantly lower renal
lipid peroxidation and reduced renal pathology as indi-
cated by the absence of renal vessel hyperplasia and
significantly reduced levels of proteinuria when compared
with the SHRSP. The oxidative stress pathway is a complex
cascade of events involving multiple types of ROS and
antioxidant enzymes. We examined several components
of this cascade, namely superoxide (O2
), hydrogen per-
oxide (H2O2), GSSG : GSH ratio and lipid peroxidation. Our
data show that ROS generated early in the oxidative stress
pathway (i.e. before point at which glutathione acts in the
ROS cascade), are not significantly different in kidneys from
SHRSP, WKY and transgenic rats. However, later compo-
nents of the pathway (GSSG : GSH ratio and lipid peroxi-
dation) are reduced in kidneys from the transgenic rats
when compared with SHRSP. In contrast, previous studies
in 20-week-old SHRSP rats demonstrated significantly
increased basal and NADH stimulated O2
 levels in renal
cortex when compared with WKY rats [50]. Several factors
may contribute to this difference in O2
 levels between the
two studies. For example, there are differences in the
methods of O2
 measurement between the studies, and
whole kidney were used in the current study as opposed to
renal cortex. However, similar to the current findings, there
were no significant differences observed in renal H2O2
levels between SHRSP and WKY rats at 20 weeks of age.
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Rat model of glutathione S-transferase m-type overexpressionROS levels in kidneys from rats at 5 weeks of age. Our data
showed that there was no evidence of oxidative stress at this
early time point in all four strains when compared with
kidneys from 21-week-old rats. Therefore, improvedGstm1
expression levels are evident in SHRSP-Tg(Gstm1)1WKY and
SHRSP-Tg(Gstm1)2WKY rats before obvious differences in
ROS levels or the onset of hypertension.
In parallel to the effect on BP, echocardiography meas-
urements at 21 weeks of age demonstrate that cardiac
hypertrophy (i.e. LVMI, relative wall thickness) and cardiac
function parameters (i.e. SV, CO) were significantly
improved in both transgenic lines compared with the
SHRSP. In line with these cardiac changes, Gstm1 mRNA
expression levels were significantly increased in WKY
hearts compared with SHRSP, with increased trends in
expression in the transgenic rats. Currently it is not possible
to determine whether the cardiac mass and function
changes are due to direct effects of altered Gstm1 expres-
sion in the heart or are a secondary effect of the significantly
lowered BP in the transgenic animals and further investi-
gation will be required to dissect these factors.
In conclusion, the production of two independently
generated Gstm1 transgenic lines on the SHRSP genetic
background has provided a unique opportunity to investi-
gate the impact of Gstm1 deficiency on the development of
hypertension and oxidative stress. This data supports the
hypothesis that reduced renal Gstm1 plays an important
role in oxidative stress mechanisms underlying the devel-
opment of hypertension and end organ damage. The clini-
cal impact of the loss of GSTM1 has recently been
demonstrated in a subset of participants from the Athero-
sclerosis Risk in Communities Study [51]. In this community-
based prospective cohort of black and white patients, zero
or one copy of GSTM1 was significantly and independently
associated with higher risk of kidney failure and heart
failure. These results suggest that GSMT1 is a potential
therapeutic target that warrants further detailed investiga-
tion, and our novel Gstm1 transgenic SHRSP lines will
provide an important experimental model for these future
preclinical studies.
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